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Summary Methotrexate (MTX) was linked, via an active ester intermediate, to a purified IgG fraction of
rabbit polyclonal antiserum raised against a cell membrane preparation from the human prostatic cell line
PC3. The resulting conjugates contained an average of 0.044 mg of MTX per mg of antibody with acceptable
losses in both the binding activity of the immunoglobulin (27.5%) and the enzyme inhibitory activity of the
drug (32% at a MTX concentration of 3 x 10-7M). Using cultures of PC3 cells the antibody-MTX
(Ab-MTX) conjugates were observed to be as effective as free drug in causing cell death and more effective
than non-immune IgG-MTX (NIgG-MTX) conjugates. When athymic nude mice bearing PC3 tumours were
administered with Ab-MTX conjugates, significant reductions in tumour growth rates were observed com-
pared to animals given saline, MTX alone or NIgG-MTX conjugates (P< 0.0I in all cases). Furthermore, the
accumulation of radioactive MTX in the tumour tissue of animals injected with these Ab-MTX conjugates
was 16-fold greater than those given free drug and 8.6-fold greater than those administered with NIgG-MTX
conjugates. Uptake by the reticuloendothelial system, however, was not significantly different when animals
from each treatment group were compared.
Following androgen ablation for the treatment of prostatic
cancer, any initial positive response is almost universally
followed by a relapse to a hormone independent state (Men-
om & Walsh, 1979). Treatment of such relapsed tumours by
chemotherapy is limited by the toxicity of the agents used,
and thus the targeting of such drugs to the tumour site may
provide a potentially more effective therapy for hormone
independent tumours, with fewer side-effects.
Antibodies have been suggested as potential carriers for
drugs (Ghose & Blair, 1978) and methods of linking the drug
methotrexate to antisera while retaining both antibody and
drug activity have been documented (Kulkarni et al., 1981).
In cultures of the prostate cell line LNCaP, incubation with a
monoclonal antiserum to human prostatic acid phosphatase
(PAP) linked to methotrexate has been shown to be more
effective than a similar conjugate in which the antiserum was
substituted by non-immune IgG (Deguchi et al., 1986).
Using this same conjugate in vivo on LNCaP tumours in
athymic nude mice, however, demonstrated that although
MTX from the conjugate accumulated more in the tumour
than free drug, accumulation was also higher in the spleen,
kidney and liver (Deguchi et al., 1986), which are known sites
of MTX toxicity. As PAP from the prostate tumour can be
released into the circulation, it is probable that immune
complexes form between the antibody in the conjugate and
circulating PAP and are taken up by the reticuloendothelial
system. Antisera raised against an antigen such as a tumour
cell membrane should provide a preferential localisation at
the tumour site and thus reduce complex formation within
the circulation. This study was therefore undertaken to assess
the effectiveness of a cytotoxic drug, methotrexate, con-
jugated to an antiserum raised against cell membranes iso-
lated from a human prostate cancer cell line PC3.
Materials and methods
Chemicals and reagents
Methotrexate (sodium salt) was purchased from Lederle Lab-
oratories (Hampshire, UK) and MTX (free carboxylic acid),
NADPH, dihydrofolate reductase, dihydrofolic acid and
NN'-dicyclohexylcarbodiimide (DCC) were purchased from
Sigma Chemical Co. Ltd (Dorset, UK). 'H-MTX (250 mCi-
(9.25 GBq) mmol-') and 5"Cr (350-600 mCi(12.95-22.2 -
GBq) mg-') were products of Amersham International plc
(Buckinghamshire, UK). N-Hydroxysuccinimide (NHS) was
supplied by Aldrich Chemical Company Ltd (Dorset, UK)
and AH Sepharose 4B was obtained from Pharmacia Ltd
(Uppsala, Sweden). Diethylaminoethyl cellulose (DE-52) was
purchased from Whatman Ltd (Maidstone, Kent, UK) and
dust-free Isoton supplied by Coulter Electronics Ltd (Luton,
UK). Both Soluene-100 and Dimilume-30 were purchased
from United Technologies (Packard, Berks., UK) and mic-
rotitre strips obtained from Costar Corporation Ltd (Camb-
ridge, UK). All tissue culture dishes and plates were supplied
by Becton-Dickinson UK Ltd (London).
PC3 cell line in vitro and in vivo
Athymic nude mice were routinely bred from Nu/Nu males
and heterozygous Nu' females and housed in polycarbonate
filter-top cages. Irradiated breeding diet (Pilsbury's Ltd, Bir-
mingham, UK) and acidified water (pH 2.8) were given ad
libitum. Controlled light and temperature conditions were
maintained with a 12 h light/dark cycle and a temperature of
20-22°C.
The human prostate cell line PC3 (Kaighn et al., 1979) was
maintained in Dulbecco's modified Eagles medium (DME)
supplemented with fetal calf serum (7% v/v), penicillin
(200 IU ml'), streptomycin (100 jig ml1), fungizone (5 ,.g -
ml-') and glutamine (1.46 mgml-'). Cultured PC3 cells re-
quired for implantation were trypsinised (trypsin 0.025%;
versene 0.02%, v/v) and resuspended in phosphate buffered
saline (PBS). The cells were injected subcutaneously into the
flanks of 6-8-week-old mice (106 cells per site) and tumours
appeared 2-3 weeks later.
Isolation ofPC3 cell membranes, immunisation ofanimals and
preparation ofan immunoglobulinfraction
Cell membranes were partially purified according to the
method of Thom et al. (1977). PC3 cell monolayers were
grown in 75 cm2 tissue culture flasks, harvested using a
cell scraper and lysed in hypo-osmotic borate/EDTA (boric
acid 0.02M, EDTA 0.2 mM, pH 10.2). The cytoplasmic
contents were expelled and gelatinised and the empty mem-
brane sacs collected by differential centrifugation (450 g for
10 min; 24,000 g for I h). Samples were routinely prepared
for electron microscopy to check for purity. An aliquot of
the membrane protein, equivalent to 5 mg of soluble protein
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(as assessed by the Bio-Rad protein assay) was injected intra-
dermally with Freund's complete adjuvant into New Zealand
white rabbits according to the multiple site injection tech-
nique described by Vaitukaitis et al. (1971). The rabbits were
boosted with the same amount of immunogen at monthly
intervals and blood samples (20 ml) obtained at 14-day inter-
vals by incision of the marginal ear vein.
IgG fractions were obtained from both immune and non-
immune sera by ammonium sulphate precipitation (45% sat-
uration) followed by ion-exchange chromatography on DE-
52 by the method described by Fahey and Terry (1973), in
which the IgG fraction was eluted from the column by
0.005 M phosphate buffer (pH 7.4). The specificity of the
antiserum was assessed by immunocytochemical techniques
on 5;Lm sections of various rat, mouse and human tissues
using the unlabelled antibody enzyme method developed by
Sternberger et al. (1970) and an adapted protocol reported
previously (Sibley et al., 1984).
Preparation ofimmunoglobulin-methotrexate conjugates
Tritiated MTX was mixed with unlabelled MTX to give a
final specific activity of 4.2fiCi (0.155 MBq) mg-' and con-
jugated to both anti-membrane IgG and normal rabbit IgG
via the active ester intermediate method described by Kul-
karni et al. (1981). MTX (30mg) was dissolved in dimethyl-
formamide (DMF, 0.4 ml) and added to N-hydroxysuccini-
mide (15.21 mg per 0.1 ml DMF) and NN'-dicyclohexylcar-
bodiimide (27.26 mg per 0.1 ml DMF). The reaction mixture
was allowed to stand at room temperature for 1 h followed
by 18 h at 4°C in the dark. The resulting precipitate was
removed by centrifugation (10,000g for 10 min) and the
supernatant containing the active ester was stored at 40C in
the dark. Determination of the amount of active ester pro-
duced was carried out using the method described by Kul-
karni et al. (1981), but employing AH Sepharose 4B columns
instead of AFFI-Gel 102. The amount of active ester was
calculated by subtracting the amount of 3H-MTX passing
through the column after binding from the amount of 3H-
MTX in the eluate following hydrolysis, and gave an average
yield of 77.6% (five separate experiments).
The active ester of MTX (1 mg in DMF) was incubated
with anti-PC3 membrane IgG or normal rabbit IgG (10 mg
per 2 ml PBS, pH 7.4) on a roller-bed for 2 h at 4°C in the
dark. Precipitated protein was removed by centrifugation
(10,000g for 10 min) and the supernatant containing the
IgG-MTX conjugates dialysed against PBS (pH 7.4) for 18 h
at 4°C, to remove free drug. Further separation from free
MTX was carried out by gel filtration on Sephadex G-50
with PBS (pH 7.4). The concentration of MTX in the con-
jugates was estimated by measurement of the radioactivity
present, and calculation with reference to the original stan-
dard of 4.2jCi (0.155 MBq) mg-1 MTX employed in the
conjugation procedure. Protein concentration in the
Ig-MTX conjugates was estimated using the Bio-Rad pro-
tein assay kit. The conjugates contained an average of 25iLg
of MTX ml-' and 560 Lg of protein ml-' of PBS.
Inhibition ofdihydrofolate reductase activity by Ab-MTX
conjugates
Pharmacological activity of MTX in the conjugate was asses-
sed by its ability to inhibit the enzymatic activity of dihyd-
rofolate reductase (DHFR) and measured spectrophotomet-
rically using the method described by Falk et al. (1976).
MTX standards and Ab-MTX conjugates (2 x 10-8 to
3 x 10-7 M) were incubated separately with the enzyme (0.1
units ml- ) at room temperature for 15 min to allow the
MTX to bind to the enzyme. Dihydrofolic acid (50jil of
0.25 mg ml-') was added to each tube and the absorbence
measured spectrophotometrically, at 340 nm, after 6 min.
Inhibition of DHFR activity was calculated using the fol-
lowing formula:
% inhibition =
DHFR activity (control)- DHFR activity (MTX or conjugates)
DHFR activity (control)
Competitive binding ofAb-MTX conjugates to PC3
membranefraction
Assessment of the binding of the Ab-MTX conjugates to
PC3 membranes was determined by a solid-phase competitive
binding assay using anti-membrane IgG labelled with 125I by
the chloramine-T method (Hunter & Greenwood, 1962).
Membrane fractions prepared from PC3 cells at a concentra-
tion of 10 gml1- in 0.1 M sodium carbonate/bicarbonate
buffer (pH 9.5) were adsorbed onto plastic microtitre plates
by incubation (100iLl per well) overnight at 4°C. Known
amounts (1-250jg proteinml-' PBS) of anti-membrane anti-
body or Ab-MTX conjugates were incubated (100 slI per
well) with 0.2gsCi (0.74 MBq) of '25I-labelled anti-membrane
antibody (2yCi mg-'; 74 MBq) at 37°C for 3 h. The wells
were washed (10 x 100 tl PBS) and the radioactivity counted
on a gamma counter. The percentage inhibition ofmembrane
IgG or Ab-MTX conjugates was calculated using the fol-
lowing formula:
% inhibition =
c.p.m. (control) - c.p.m. (anti-membrane IgG or conjugates)
c.p.m. (control)
x 100
The loss of binding activity displayed by the Ab-MTX
conjugates was then calculated from the following formula:
% loss of inhibition=
% inhibition (anti-membrane IgG) - % inhibition (conjugates)
% inhibition (anti-membrane IgG)
x 100
Assessment ofthe cytotoxicity ofthe Ab-MTX conjugates in
vitro
Estimation ofcell number and cell size distribution The cyto-
toxicity of the Ab-MTX conjugates was assessed by measur-
ing the number of cells remaining in the cultures after treat-
ment in comparison to controls. Monolayers of PC3 cells
were subcultured with trypsin/versene and seeded onto 24-
well plates at a density of 5 x 103 cells ml1' DME. The cells
were allowed to recover from trypsinisation for 24 h at 37°C
before incubation with Ab-MTX conjugates (90lag Ab ml-1,
4tg MTX ml-'), Ab alone (90pg mI 1), MTX alone
(0.4-4 tLg ml '), Ab plus MTX combined but not conjugated
(90 lg AbmIh', 4tLg MTXml1'), NIgG-MTX conjugates
(83tgg IgGml ', 4,ug MTXml ') in DME, or DME alone
(control) for 2 h at 37°C, using quadruplicate cultures per
experimental group. After this time medium was aspirated
from the wells, the cultures washed with PBS (5 x 2ml),
fresh medium (1 ml) added to each well and the cultures
incubated for 72 h at 37C. Cells were counted at the end of
this period by disrupting the monolayers with trypsin/EDTA
and diluting the cells with Isoton (15 ml). The suspended cells
were counted on a Coulter counter (model ZB1) equipped
with a multichannel analyser facility and an x-y plotter.
Total cell population per well was determined by taking
account of machine coincidence error, sample volume and
dilution of the suspension. Any accumulation of cells within
a certain phase of the cell cycle was determined by analysis
of the cell size distribution of each experimental group using
the multichannel analyser.
Release of 5"Cr from pre-loaded cells Release of 5"Cr from
pre-loaded PC3 cells was measured by a modification of the
method described by Wigzell (1965), and gives an estimation
of cell death. PC3 cells were seeded onto 24-well plates, at a
density of 5 x 103 cells ml' and allowed to recover from
trypsinisation for 24 h at 37°C. Pre-labelling of the cells was
carried out by the addition of 51Cr in DME (20fsCi704 A.J. ROWLAND et al.
(0.74 MBq) x 106 cells) for 30 min and each well washed
individually with PBS (6 x 2 ml). Monolayers of PC3 cells
were incubated with Ab-MTX conjugates (90 fig Ab ml',
4 lag MTX ml1'), Ab alone (90Og ml-') MTX alone
(0.4-4 gg ml-'), Ab plus MTX combined but not conjugated
(90 gig Ab ml', 4 gig MTX ml1'), NIgG-MTX conjugate
(83figIgGml-'; 4fig MTX ml-') in DME, or DME alone
(control) for 2 h at 37°C. After this time the media was
aspirated from the cells, each well washed with PBS
(5 x 2 ml) and fresh medium added (1 ml) to each culture.
The 5'Cr released from the cells was measured 24 h later by
removal of the media, washing each well individually
(2 x 2 ml DME) and counting the total radioactivity in the
medium from each well on a gamma counter.
Assessment ofthe cytotoxicity ofAb-MTX conjugates in vivo
The anti-tumour activity of the Ab-MTX conjugates was
assessed in vivo by their action on the growth of PC3 tu-
mours in athymic nude mice. Mice bearing subcutaneous
tumours (0.3-1.1 cm diameter) were divided into six groups
(16 animals per group) and injected with Ab-MTX con-
jugates, Ab alone, MTX alone, Ab + MTX combined but
not conjugated, NIgG-MTX conjugates or saline. Drug and
antibodies were administered i.m. every 48 h for 12 days at a
dose of 1 mg kg- 3H-MTX (22 gig per animal) in saline
(100 gl) and an antibody concentration equivalent to that
found in the Ab-MTX conjugate (approximately 498 gig per
animal). Tumour size was recorded every 2 days as the mean
of two perpendicular diameters, one across the greatest
width, and the tumour volume estimated using the formula
4/3 r3, where r is the mean radius. Tumour volume cal-
culated in this way was found to have a linear relationship
with both tumour weight and tumour volume as measured by
water displacement. The errors involved in using this formula
were found to be negligible.
Tissue distribution of3H in animals treated with Ab-MTX
conjugates
Twenty-four hours after the sixth injection of the animals
under study, the animals were anaesthetised, bled by cardiac
puncture and killed by cervical dislocation. The tumour and
various body tissues were excised and known amounts (up to
100 mg wet weight) were individually placed in counting
vials. Tissues were solubilised by the addition of Soluene
(1 ml) and incubated at room temperature for up to 48 h
before the addition of Dimilume scintillation fluid (5 ml). The
radioactivity in each sample preparation was determined by
scintillation counting and quenching corrected for by internal
standardisation. The concentration of MTX in the tissues
was estimated per g wet weight of tissue by extrapolation
from the specific activity of the starting material of 3H-MTX
(4.2 giCi (0.155 MBq) mg-').
Statistical evaluation
A Mann-Whitney U test was used to compare the treatment
data derived from 5'Cr release and cell population studies in
vitro and also from the tissue distribution of 3H-MTX from
the various treatment groups studied in vivo. Tumour volume
data were analysed by two-way analysis of variance
(ANOVA) providing values for an F statistic and hence a P
value, reflecting the level of statistical significance.
Results
Conjugation procedures and assessment ofantibody and drug
activity
Methotrexate was conjugated to anti-membrane IgG and
non-immune IgG via an active ester intermediate. The extent
of substitution was 14.6 mol of MTX per mol of IgG with a
64% recovery and a 27.5% loss in immunological activity, as
assessed by a competitive binding assay (Table I).
The immunoglobulin fraction used in this study was not
completely specific for prostatic tissue as assessed by immun-
ocytochemical techniques. At an antibody dilution of 1/500
(PBS, pH 7.5), human breast, bladder, kidney and intestinal
epithelium also exhibited some staining although with a
much lower intensity than that observed with benign and
carcinomatous prostatic tissue. Staining was always assoc-
iated with the epithelial cell membrane and no cross-reac-
tivity was observed with any mouse or rat tissues. When
equivalent concentrations of Ab and Ab-MTX conjugates
were compared in the immunocytochemical procedure, no
diminution in membrane staining or change in tissue
specificity of the antibody was observed after conjugation
(data not shown).
Comparison of free MTX and Ab-MTX conjugates to
inhibit the enzyme activity of DHFR indicated that the MTX
within the conjugate retained approximately 68% of its abil-
ity to bind to the enzyme at a drug concentration of
3 x 10-7 M (Figure 1).
Cytotoxicity testing in vitro
Cytotoxicity testing was carried out using cultured PC3 cells,
each experiment being carried out at least three times. Con-
jugate and drug concentrations were adjusted to 4jLg
MTX ml-' unless otherwise stated, and antibody concentra-
tions to 90fig protein ml-' (equivalent to the amount of Ab
in the Ab-MTX conjugates at 4jigml-'). Incubations with
drugs and conjugates were carried out for 2 h at 37°C and
the results expressed as the means from quadruplicate cul-
tures.
Estimation of cell number The differences in cell population
with the various treatments are shown in Figure 2 and are
expressed as number of cells per ml of medium. Incubations
with increasing concentrations of MTX (0.4-4jig ml-') pro-
duced a progressive decrease in the number of cells, at
4figml1' MTX the value being 14.6% of the control popula-
tion. The Ab-MTX conjugates reduced the cell population
to 14.9% of the control, and no significant difference was
observed between the values obtained for Ab-MTX con-
jugates and free drug (4figml-').
Significantly larger cell numbers were observed (P<0.05)
when the PC3 cells incubated with NIgG-MTX conjugates
were compared to cells treated with Ab-MTX conjugates.
The addition ofmembrane Ab alone to cultured cells led to a
reduction in cell number compared to controls (P<0.05).
Cultures incubated with Ab plus MTX, combined but not
conjugated, however, displayed a larger cell population than
incubation with MTX alone (P<0.05).
Cell size distribution As the inhibition of DHFR leads to
inhibition of DNA, RNA and protein synthesis (Bertino,
1963), cells treated with MTX would be expected to be
TableI Competitivebindingofunlabelledanti-membraneantibodyor
antibody-methotrexate conjugate with '25I-antibody in a solid-phase
assay using PC3 membrane
% inhibition of
25I-antibody binding
Concentration of MTX-antibody % loss ofbinding activity
antibody (jig) conjugates Antibody in the conjugates
250 48.7 66.3 26.5
100 40.2 56.8 29.2
50 39.3 52.5 25.1
25 31.2 45.7 31.7
10 28.2 37.6 25.0
PC3 membrane fractionswereadsorbed ontomicrotitre wells(100jLg
protein per well) and known amounts (1-250gIg) of Ab-MTX
conjugates or Ab were incubated with '25I-labelled Ab (2gLCi,
7.4 MBqmg-1; 100jg per well) for 3 h at 37C. After washing,
(10 x 100 gl PBS) total radioactivity was assessed per well. Data are
expressed asthemeanpercentageinhibitionfrom 16experimental wells.Ab-MTX CONJUGATES: EFFECT ON PC3 TUMOURS 705
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Figure 1 The inhibition of dihydrofolate reductase (DHFR) by
MTX ( ) and Ab-MTX conjugates ( ---). Methotrexate
and Ab-MTX conjugates (2 x 10-8 to 3 x 10-7 M, 100il per
tube) were incubated with the enzyme (0.1 units per tube) in the
presence of NADPH (16.6ILg) for 15 min at 25°C. Dihydrofolic
acid (12.5 iLg in 50 1l) was dispensed into each tube and the
change in absorbance measured spectrophotometrically at 340 nm
after 6 min.
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Figure 2 The effect of the Ab-MTX conjugates on the number
of PC3 cells remaining in culture after treatment. PC3 cells
(5 x 103 per well) were incubated with DME (I ml) containing
MTX (0.4-42Lgml4'), Ab-MTX conjugates (904g Ab ml-';
4pg MTXml-'), NIgG-MTX conjugates (83fg IgG-ml-'1; 4tLg
MTX ml-0').Ab alone (90 Lg ml-'), Ab + MTX (90 Lg Ab, 4pg
MTX ml-') or DME alone. Treatments were carried out for 2 h
at 37°C, the media removed from each well and replaced with
fresh DME (I ml). After a further incubation of 72 h cells were
trypsinised, diluted with Isoton and total cell population per well
measured on a Coulter counter. Data represent mean and + s.d.
of quadruplicate cultures.
arrested in the S phase of the cell cycle. The distribution of
cell size within control and drug treated cultures was
expressed as the number of cells against cell volume (Figure
3). Control cultures displayed a distribution pattern as seen
Figure 3 The distribution of PC3 cell volume in vitro within
various experimental groups. PC3 cells (5 x 103 per well) were
incubated with MTX (4fLgml-'), Ab-MTX conjugates (90pg
Abml-'; 4pg MTX ml-'), NIgG-MTX conjugates (83 Lg
NIgG ml- ; 4gLg MTX ml )Ab alone (90 gig Ab ml-'), or DME
alone for 2 h at 37C. Cultures were washed (5 x 2 ml PBS) fresh
media (1 ml) added to each well and the cells incubated for a
further 72 h). After trypsinisation cells were diluted with Isoton
and cell population size determined on a Coulter counter. Cell
volume data was obtained from multichannel analysis of Coulter
counts. a, Control MTX ( ..... ); b, Ab Ab-MTX
conjugates ( ), NIgG-MTX conjugates ( ----).
in Figure 3a and cells treated with Ab alone had an identical
profile (Figure 3b). Incubation of the cells with NIgG-MTX
conjugates showed a slight shift towards a larger cell volume
(Figure 3b), whereas cultures treated with either MTX alone
(4 gg ml-', Figure 3a) or Ab-MTX conjugates (Figure 3b)
displayed a pronounced shift towards larger cell volumes
indicating an accumulation of cells in the S phase of the cell
cycle for these latter two treatments.
The release of5'Crfrom pre-loaded cells The release of "1Cr
into the medium from pre-loaded PC3 cells incubated with
the various drug concentrations and conjugate are shown in
Figure 4 and expressed as d.p.m. ml-'. With increasing con-
centrations of MTX there was a progressive rise in the
amount of 5'Cr liberated from the cells, reaching a value 5.6
times higher than the control of 4 gig ml-' of drug. Essen-
tially similar results were observed after incubation of the
cells with Ab-MTX conjugates as obtained with free drug.
The NIgG-MTX conjugates were not as effective in causing
the release of 5'Cr from the cells as the Ab-MTX conjugates
(P<0.05), but did display some cell killing activity as the
5'Cr content of the media was significantly larger than that
seen in control cultures (P<0.01). Cells treated with mem-
brane Ab plus MTX displayed a significantly lower liberation
of 5'Cr than that observed with free MTX alone (P<0.05).
Incubation of the cultured cells with membrane Ab alone
demonstrated a higher release of 5'Cr into the medium than
determined in medium from control cultures (P<0.05).
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Figure 4 The effect of the Ab-MTX conjugates on the libera-
tion of 5'Cr from pre-loaded PC3 cells in vitro. PC3 cells (5 x 103
per well) were incubated with 5' Cr (201Ci (0.74 MBq) x 106
cells) for 30 min at 37C before treatment with MTX (0.4-4pjg
ml-'), Ab-MTX conjugates (90pg Ab, 4 Ig MTX ml-'),
NIgG-MTX conjugates (83 gig IgG, 4 gg MTX ml-'), Ab alone
(90Oigml-'), Ab+MTX (9Oig Ab, 4pg MTX ml-) or DME
alone. Incubations were carried out for 2 h at 37C, the cells
washed (5 x 2 ml PBS) and fresh media (1 ml) added to each
well. The media was removed from each well 24 h later and the
radioactivity measured on a gamma counter. Data represents the
mean + s.d. from eight wells per experimental group.
Assessment ofthe cytotoxicity ofAb-MTX conjugates in vivo
Measurement of the size of individual PC3 tumours growing
in mice receiving the various drugs and conjugates was car-
ried out over a 12-day period and is expressed as the percen-
tage change in tumour volume against time (Figure 5). Con-
trol animals, treated with saline only, showed a 15-fold inc-
rease (mean from 16 animals) in tumour volume over the
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Figure 5 The effect of Ab-MTX conjugates on the growth of
PC3 tumours in vivo. Athymic nude mice bearing subcutaneous
PC3 tumours (0.3-1.1 cm diameter) were injected i.m. with
MTX Ab-MTX conjugates, NIgG conjugates, Ab alone, Ab +
MTX or saline every 48 h over a period of 12 days. Each dose
was adjusted to I mg MTX kg-' body weight (22 fig per animal
in 100 gil saline) and the amount of Ab given to the control
groups was equivalent to the concentration of Ab present per
22 gig of MTX in the Ab MTX conjugates. Tumour size was
measured with calipers before each injection and tumour volume
calculated from the formula 4/3 -r. Data are expressed as a
percentage increase in tumour volume from day 0, each value
representing the mean from 16 experimental animals, and the
standard errors of the mean.
12-day period studied. Although NIgG-MTX conjugates
appeared to suppress tumour growth, analysis of variance on
the tumour data showed no significant difference from cont-
rols. Injections of MTX alone, Ab alone or Ab plus MTX
resulted in a significant inhibition of tumour growth when
compared to the control group (P<0.002). Animals treated
with Ab-MTX conjugates, however, displayed an inhibition
of tumour growth that was significantly greater than all other
treatment groups (P<0.001).
Distribution of3H-MTX in vivo
The Ab-MTX conjugates, NIgG-MTX conjugates and free
MTX given to animals all contained 3H-MTX (4.2 gCi
(0.155 MBq) mg-' MTX). Measurement of the label was
undertaken in five animals from each treatment group in
order to assess the uptake and distribution of the tritium
label within the animals. The results for each tissue and
treatment are expressed as ng MTX g-' wet weight of tissue
and also as tissue:blood ratios (Table II). The highest ac-
cumulation of radioactivity was observed in the tumours of
animals treated with Ab-MTX conjugates, the tumour:
blood ratio being 59.7, compared with 7.4 for animals trea-
ted with MTX alone, 6.6 for those given Ab plus MTX and
6.3 for those receiving NIgG-MTX conjugates. The results
show (Table II) that the distribution of label in the lung,
heart, kidney, liver, spleen and skin vary slightly, but not
significantly between the treatment groups.
Significantly higher levels of radioactivity (P<0.05) were
observed within the blood of animals given Ab-MTX con-
jugates or NIgG-MTX conjugates compared to those receiv-
ing free drug indicating a difference in the rate of clearance.
Discussion
To maintain therapeutic effectiveness ofcytotoxic drug linked
to antibodies, conjugation should not lead to a substantial
loss in either drug activity or in antibody binding and
specificity. Therefore, in this present study the resulting con-
jugation of methotrexate with a polyclonal antiserum raised
against a prostatic tumour cell line PC3 was assessed in
several systems which examined both the drugs cytotoxic
ability in vitro and in vivo and the localisation in vivo.
The retention of antibody activity after conjugation with
Table II Tumour and tissue distribution of3H-MTX and conjugated
3H-MTX in vivo
Tissue distribution of3H-MTX, ngg' wet weight
MTX-Ab MTX-NIgG
Tissue MTX Ab + MTX conjugates conjugates
Lung 290.2 ( 6.9) 244.9 ( 5.0) 185.9 ( 2.1) 201.7 ( 2.1)
Heart 394.4 ( 9.4) 234.1 ( 4.8) 156.8 ( 1.8) 234.4 ( 2.4)
Kidney 718.5 (17.1) 474.6 ( 9.7) 1064.0 (12.2) 972.7 (10.1)
Liver 906.5 (21.6) 777.9 (15.9) 1063.7 (12.2) 1674.4 (17.4)
Spleen 185.4 ( 4.4) 353.8 ( 7.2) 293.7 ( 3.4) 471.3 ( 4.9)
Skin 230.8 ( 5.5) 293.0 ( 6.0) 306.2 ( 3.5) 619.4 ( 6.4)
Tumour 312.1 ( 7.4) 323.8 ( 6.6) 5214.8 (59.7) 604.2 ( 6.3)
Blood 41.9 48.8 87.4 96.4
Athymic nude mice bearing palpable PC3 tumours (0.3 -1.1 cm
diameter) were injected with MTX, Ab + MTX conjugates,
NIgG-MTX conjugates or Ab + MTX every 48 h over a period of 12
days. Each doseofMTX wasadjusted to I mg kg-' body weight (221sg
peranimal in 100!Ll saline)and theconcentration ofAbgiven tocontrol
animals adjusted to the equivalent amount in the Ab-MTX conjugate
(498fg per animal in 100gul saline). Animals were bled by cardiac
puncture 2 h after the last injection, killed and the various body tissues
removed. Tissues (up to 100mg wet weight) were solubilised with
Soluene (1 ml) and the amount of 3H label measured by scintillation
counting. Quenchcorrectionwascarriedoutbyinternalstandardisation
and the total amount ofMTX present calculated with reference to the
original starting material (4.2 uCi(O.155 MBq) mg-'). Data are ex-
pressedasngMTX pergwetweightoftissueeachvaluerepresentingthe
mean from five experimental animals. Tissue:blood ratios are given in
parentheses.Ab-MTX CONJUGATES: EFFECT ON PC3 TUMOURS 707
the least interruption in structure and activity is clearly of
major importance, excess drug linkage or adverse reaction
conditions leading to denaturation or aggregation of the
antibody. In the studies described in this paper, conjugation
by an active ester intermediate method produced a molar
incorporation ratio ofdrug to antibody of 14.6 with a 72.5%
retention of antibody binding, as estimated by quantitative
membrane binding analysis and no detectable change in
membrane specificity as assessed by immunocytochemical
techniques. A similar molar ratio was reported for conjuga-
tion of methotrexate with a monoclonal antibody against
prostatic acid phosphatase which retained over 90% of its
antibody activity (Deguchi et al., 1986). Such differences may
be explained by the availability of amino groups on the
particular immunoglobulins under study, an idea supported
by the results of Kanellos et al. (1985), who noted that
although conjugation of methotrexate to two separate
monoclonal antibodies produced the same molar ratio of
drug and antibody their retention of antibody activity was
markedly different.
Assessment of drug activity by the inhibition of dihyd-
rofolate reductase showed some loss in the capacity of meth-
otrexate to inhibit the enzyme when conjugated compared to
an equimolar amount of free drug (Figure 1). Such losses of
dihydrofolate reductase inhibition have been reported prev-
iously when methotrexate was conjugated to several different
macromolecules (Deguchi et al., 1986; Fung et al., 1979;
Garnett et al., 1983; Kanellos et al., 1985; Kulkarni et al.,
1985; Tsuro et al., 1980) and is probably due to the stearic
interference of the macromolecule with the binding of the
pteridine moiety of the methotrexate to the active site of the
enzyme (Baker, 1969). Studies suggest that a reduced ability
to inhibit dihydrofolate reductase activity also occurs within
the cell. Deguchi et al. (1986) observed that methotrexate
conjugated to immunoglobulin was less effective than free
drug at inhibiting the incorporation of 3H-deoxyuridine by
LNCaP cells in culture, even though methotrexate in the
conjugated form was taken up to a greater extent than free
methotrexate. This finding is supported by Uadia et al.
(1985), who showed that when human melanoma cells were
treated with 3H-methotrexate-antibody conjugates, 35% of
the radioactivity was found in the low molecular weight
fraction and the methotrexate derivatives in this fraction
were no more potent inhibitors of dihydrofolate reductase
than the original conjugate. Their study suggests that the
methotrexate derivatives digested within the cell are biolog-
ically less potent than free drug.
In our tissue culture experiments, determination of the cell
volume distribution patterns (Figure 3) revealed that the
antibody methotrexate conjugate displayed the same profile
as methotrexate alone. As the inhibition of dihydrofolate
reductase by methotrexate ultimately results in the cessation
of purine and amino acid synthesis (Bertino, 1963), the al-
tered distribution pattern displayed by the cultures incubated
with free drug compared to control cultures would be ex-
pected, reflecting the accumulation of arrested cells in the S
phase of the cell cycle. The similar profiles obtained with cells
treated with both the antibody-methotrexate conjugates and
with free drug would therefore indicate that the methotrexate
moiety of the conjugate was still able to inhibit dihydrofolate
reductase activity within the cell and hence arrest the cells in
S phase, even though potency of the drug may be reduced.
Conjugation of cytotoxic drugs to non-immune IgG have
been shown to produce a greater inhibition of tumour cell
growth than free drug alone (Hurwitz et al., 1979; Johnson et
al., 1981; Kulkarni et al., 1985). In the experiments reported in this paper, non-immune IgG-methotrexate conjugates
were significantly less effective than either methotrexate alone
or antibody-methotrexate conjugates in reducing the cell
number (Figure 2) and causing in the release of 5'Cr from
cells in vitro (Figure 4). Furthermore, these non-immune
conjugates did not significantly reduce tumour growth in vivo
(Figure 5). Analysis of cell size distribution after incubation
of the PC3 cells with the various drugs and conjugates demonstrated that the non-immune methotrexate conjugates
failed to display the same distribution profile observed with
free drug or antibody-methotrexate conjugates (Figure 3).
Assuming that both immunoglobulin conjugates are broken
down within the cell in the same manner, the results would
suggest that the non-immune conjugates are unable either to
bind or to enter the cell to the same extent. Such non-
immune immunoglobulin conjugates appear to rely upon
non-specific uptake by the cell and discrepancies in data from
different laboratories may be due to the amount of non-
specific binding regions on the cell surface or the pinocytoic
activity of the cell line under study. An altered clearance rate
may also contribute to differences found in vivo.
Specific antibody-methotrexate conjugates have been re-
ported to enter the cell as a consequence of antibody binding
and subsequent endocytosis (Smyth et al., 1987) rather than
via the active carrier-mediated transport system used for
methotrexate or by the non-specific uptake of non-immune
conjugates. Assessments of the cytotoxic effectiveness of the
antibody-methotrexate conjugates in vitro, using measure-
ments of both 5"Cr release from pre-loaded cells (Figure 4)
and cell population parameters (Figure 2) demonstrated that
these conjugates were not significantly different in action
from an equimolar amount of free drug, even though the
dihydrofolate reductase inhibitory activity of the conjugates
was reduced. It would appear therefore that the membrane
antibody-methotrexate conjugates are efficiently incorpor-
ated into the cells after interaction of the antibody with the
cell surface and that the methotrexate from the conjugates is
sufficient to cause inhibtion of dihydrofolate reductase.
When a drug and tumour specific antibodies have been
admininstered in combination, but not conjugated, several
workers have observed a more potent cytotoxic action than
free drug given alone (Kulkarni et al., 1981; Lee & Hwang,
1979; Tai et al., 1979) and in some cases an enhanced effect
has been observed over the conjugate (Hurwitz et al., 1978).
No such synergistic effect between drug and antibody could
be demonstrated in our study and may be explained by the
high affinity of the polyclonal antiserum utilised for the cell
membrane. As a carrier mediated active transport system has
been reported for methotrexate (Goldman et al., 1968) it is
possible that enhanced binding of the antibody to the cell
membrane in our study may block this carrier system, thus
hampering drug transport. High affinity membrane binding
might also explain the cytotoxicity of the antibody when
given alone, both in vitro (Figures 2 and 4) and in vivo
(Figure 5). Antibody cytotoxicity is well documented (Motta,
1971) and antibodies against tumour associated cell surface
antigens have been demonstrated to produce membrane med-
iated cell changes either directly (Yang & Vas, 1970) or
through complement and other intermediaries both in vitro
and in vivo (Ghose et al., 1977).
When anti-membrane antibody-methotrexate conjugates
were given to nude mice bearing PC3 tumours, a highly
significant reduction in tumour growth was observed when
compared to all other treatment groups (Figure 5). The
concentration of 3H-methotrexate in the tumours of animals
given these conjugates were significantly higher than controls
(P<0.01 in all cases, Table II). Animals treated with both
specific anti-membrane antibody and non-immune antibody
conjugates displayed significantly higher blood levels of 3H-
methotrexate than animals receiving drug in its free form
thus indicating a slower clearance rate. Few studies have
involved measurement of the in vivo distribution of cytotoxic
drugs linked to antibodies. Deguchi et al. (1986) reported an
increase of 3H in the liver and kidney of animals given a
conjugate of methotrexate linked to a monoclonal antibody
against prostatic acid phosphatase (PAP). As PAP is a secre-
tory product of prostatic cells it is conceivable that its release
into the blood stream is sufficient to elicit the formation of
antibody complexes, which would then be taken up by the
reticuloendothelial system. This may explain the elevated
levels of radioactivity labelled conjugate within the liver and
kidneys of their animals in comparison to controls. Selection
of an antiserum against prostatic cell membranes for con-
jugation with a cytotoxic drug, in preference to one against708 A.J. ROWLAND et al.
secretory products of the cells, should reduce the possibility
of antibody complexes forming within the blood. Indeed in
our study treatment with the anti-membrane antibody-meth-
otrexate conjugates significantly increased drug accumulation
at the tumour site without increasing the level of drug in the
other body tissues, suggesting that uptake by the reticuloen-
dothelial system was not pronounced.
Although it would appear that the anti-membrane anti-
body-methotrexate conjugates described in this study pro-
vided an efficient means for specificity targeting the drug in
vivo, other anti-membrane antibody conjugates do not appear
to produce such significant tumour reduction (Kanellos et al.,
1987; Smyth et al., 1986). As the antibody preparation
employed in this study consisted of a purified rabbit poly-
clonal antiserum to prostate membranes, its effectiveness in
vivo may probably relate to the existence of numerous anti-
bodies to various cell surface antigens. A cocktail of three
monoclonal antibodies against the surface of T lymphocytes,
linked to the toxin ricin, was found to be more effective in
inhibiting T cell proliferation than any single monoclonal
antibody (Vallers et al., 1983). The approach of using a
battery of antibodies against various antigenic determinants
on the cell membrane may therefore provide a more efficient
carrier system for drug targeting.
The polyclonal antibody used in this study was, as stated,
not specific for its prostate cell target and we are fully aware
of the need for a battery of anti-membrane monoclonals
preferential to human prostatic epithelial cells for future
targeting and clinical studies.
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